The Behavioral and Functional Neuroscience Laboratory offers a wide range of disease models:
T41b transgenic mice show mature amyloid-beta plaques, pathological hallmarks of AD, in the frontal cortex as early as 3-4 months of age and develop plaques in the hippocampus, thalamus, olfactory region, basolateral amygdala, and subiculum at the age of 5-7 months.
PS19 transgenic mice express the P301S mutant form of human tau and develop progressive accumulation of neurofibrillary tangles with age. Thus, the strain is commonly used as a model of tauopathy, such as Alzheimer's Disease.
Back to top
Ts65Dn mice are the most commonly used mouse model of Down Syndrome (DS). This mouse is generated by Robertsonian segmental translocation of mouse chromosome 16 (MMU16) to the MMU17 centromere. This chromosomal segment contains an extra copy of more than 100 gene homologues to HSA21. Ts65Dn mice have shorter life expectancies and show morphological, neurological, and structural abnormalities that parallel those found in patients with DS.
Middle Cerebral Artery occlusion involves temporarily or permanently restricting MCA blood flow to the cortex and striatum by inserting intraluminal suture in the internal carotid via an incision in the external carotid. The suture lodges in the junction between the anterior and middle cerebral arteries and remains in place either for a predetermined amount of time or permanently.
R6/2 transgenic mice display progressive phenotype reminiscent of Huntington Disease (HD) in humans, including choreiform-like movements, involuntary stereotypic movements, tremor, and epileptic seizures, as well as non motor symptoms, including unusual vocalization. Frequent urination and loss of body weight and muscle bulk occurs with disease progression. Neurological developments include Neuronal Intranuclear Inclusions, which contain both the huntingtin and ubiquitin proteins. Onset of HD symptoms occurs between 15 and 21 weeks of age. This line is transgenic for the 5' end of the human HD gene carrying approximately 120 +/- 5 (CAG)repeat expansions.
Two Vessel Occlusion Global Ischemia (stroke)